ELECTRONIC SUPPLEMENTARY MATERIAL―Online Only from Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
David S. Hong(The University of Texas MD Anderson Cancer Center), Manish R. Patel
Cited by 0
Related Papers
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
|Nature Medicine|2023|185
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2019|88